ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Basic studies have showed that melatonin is associated with myocardial infarction and heart failure. However, no study has evaluated whether melatonin is associated with adverse clinical outcomes in STEMI patients.
Study Type
OBSERVATIONAL
Enrollment
1,700
a change in the prevalence of no-reflow
Thrombolysis in myocardial infarction (TIMI) flow grade of \<3 with a myocardial blush grade of 0-1 was defined as angiographic no-reflow
Time frame: mediately after percutaneous coronary intervention (PCI)
in-hospital complications
defined as acute heart failure, atrial fibrillation, chest pain or recurrence of myocardial infarction, complete atrioventricular block, cerebrovascular disease, ventricular fibrillation or ventricular tachycardia
Time frame: up to 2 weeks after PCI
in-hospital major adverse cardiac or cerebrovascular events
the composite of death, nonfatal MI, or stroke
Time frame: up to 2 weeks after PCI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.